Brief: SK Biopharmaceuticals Co Signs $17 Million Deal With SK Life Science Inc To Sell Cenobamate In U.S.
26/09/2022 02:34
Sept 26 (Reuters) - SK Biopharmaceuticals Co Ltd
326030.KS :
* SK BIOPHARMACEUTICALS CO: SIGNS $17 MILLION DEAL WITH SK
LIFE
SCIENCE INC TO SELL CENOBAMATE IN U.S.
Further company coverage: 326030.KS
(Reporting by Soo-hyang Choi)
((soohyang.choi@thomsonreuters.com;))
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker